论文部分内容阅读
目的:探讨阿托伐他汀、罗格列酮及两药联合应用对大鼠急性缺血再灌注(I/R)心肌的作用及可能机制。方法:将健康雄性SD大鼠63只随机分5组:假手术组(7例)、I/R组(14例)、阿托伐他汀组(14例)、罗格列酮组(14例)、阿托伐他汀+罗格列酮组(14例)。灌胃1周后制作大鼠在体心肌I/R模型。再灌注后,测定血清心肌酶及一氧化氮(NO);心肌组织丙二醛(MDA)及总超氧化物歧化酶(TSOD);Evansblue、TTC双重染色后,用计算机图像分析软件计算梗死面积。结果:阿托伐他汀组、罗格列酮组、阿托伐他汀+罗格列酮组与I/R组比,心肌梗死面积减少,乳酸脱氢酶(LDH)、肌酸激酶(CK)降低,NO升高;TSOD升高、MDA降低(P<0.01)。阿托伐他汀+罗格列酮组较阿托伐他汀组、罗格列酮组心肌梗死面积减少;LDH、CK降低,NO升高;TSOD升高、MDA降低(P<0.01);较假手术组NO、TSOD降低,MDA升高(P<0.01),LDH、CK升高(P>0.05)。阿托伐他汀组与罗格列酮组各指标水平接近(P>0.05)。结论:阿托伐他汀、罗格列酮及两药联合应用能明显减轻心肌I/R损伤;其作用机制与增加NO含量、提高心肌组织TSOD活性,降低MDA含量有关。
Objective: To investigate the effect and possible mechanism of atorvastatin, rosiglitazone and their combination on acute myocardial ischemia / reperfusion (I / R) in rats. Methods: Sixty-three healthy male Sprague-Dawley rats were randomly divided into 5 groups: sham operation group (n = 7), I / R group (n = 14), atorvastatin group (n = 14), rosiglitazone group ), Atorvastatin + rosiglitazone group (14 cases). One week after gavage, I / R model of rat myocardium was made. After reperfusion, serum myocardial enzymes and nitric oxide (NO), myocardial MDA and total superoxide dismutase (TSOD) were measured. After double staining with Evansblue and TTC, infarct size was calculated by computer image analysis software . Results Compared with I / R group, the area of myocardial infarction was decreased in atorvastatin group, rosiglitazone group and atorvastatin + rosiglitazone group, and the levels of LDH, CK, Decreased, NO increased; TSOD increased, MDA decreased (P <0.01). Compared with atorvastatin group and rosiglitazone group, the area of myocardial infarction in atorvastatin group and rosiglitazone group decreased; LDH, CK decreased, NO increased, TSOD increased, MDA decreased (P <0.01) In the operation group, NO, TSOD decreased, MDA increased (P <0.01), LDH, CK increased (P> 0.05). Atorvastatin group and rosiglitazone group indicators close to (P> 0.05). Conclusion: Combination of atorvastatin, rosiglitazone and the two drugs can obviously reduce the myocardial I / R injury. Its mechanism of action is related to increasing NO content, increasing myocardial TSOD activity and decreasing MDA content.